-

Eurofins Technologies Launches a New Multiplex RT-PCR Assay for Combined SARS-CoV-2 Screening and Rapid Detection of the Omicron (B.1.1.529) Variant of Concern

LUXEMBOURG--(BUSINESS WIRE)--Eurofins Technologies (Paris:ERF) announces the launch of the multiplex RT-PCR assay GSD NovaType Detect + Select K417N SARS-CoV-2. Within just one week since the first reports on the Omicron variant of concern, this kit has been developed as a quick response to identify its presence. The assay is designed for the simultaneous qualitative detection of SARS-CoV-2 genomic RNA and identification of the spike (S) mutation K417N in one reaction.

The results of this RT-PCR assay can be obtained within 1 hour, which makes it a fast and cost-effective solution to identifying the presence of the Omicron variant before samples are confirmed by whole genome sequencing.

Eurofins Technologies is constantly working to adapt its product offering to meet the challenges of the ongoing COVID-19 pandemic..

For more information, please visit Eurofins Technologies website.

About Eurofins Technologies – a fast growing provider of diagnostic technologies in the field of immunoassays and molecular detection methods

Building on the experience and scientific excellence of the Eurofins Group, Eurofins Technologies is a fast growing global provider of diagnostic technologies and industry-leading ELISA-based instruments in the field of bioanalytical testing for the food, feed, environmental, animal health, and clinical diagnostics industries.

About Eurofins – the global leader in bio-analysis
Eurofins is Testing for Life. With 55,000 staff across a network of 900 laboratories in over 50 countries, Eurofins’ companies offer a portfolio of over 200,000 analytical methods.

Eurofins Shares are listed on Euronext Paris Stock Exchange.

Contacts

Rodrigo Berlie
ir@eurofins.com

Industry:

Eurofins Scientific

BOURSE:ERF
Release Versions
EnglishSpanish (Summary)GermanFrenchItalianDutch (Summary)

Contacts

Rodrigo Berlie
ir@eurofins.com

More News From Eurofins Scientific

Eurofins CDMO Alphora Announces Integration of Advanced Continuous Flow Technology in API Manufacturing

MISSISSAUGA, Ontario--(BUSINESS WIRE)--Eurofins CDMO Alphora is excited to announce the expansion of its Active Pharmaceutical Ingredient (API) manufacturing capabilities through the integration of advanced, custom-built Continuous Flow (CF) technology to its operations. The company is receiving advisory services and research and development funding support from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) for this project. Developed in-house by Euro...

Eurofins to Divest Its Electrical & Electronic Testing Business

LUXEMBOURG--(BUSINESS WIRE)--Regulatory News: Eurofins Scientific SE (the “Company” or “Eurofins”) (EUFI.PA) (Paris:ERF) announces the signing of an agreement to divest its Electrical & Electronic Testing business (“MET Labs”) to UL Solutions Inc. for an Enterprise Value of €575 million on a cash and debt free basis. MET Labs is expected to generate over €180 million in revenues in 2026, with profitability broadly in line with the Group average, and employs approximately 1,300 staff globall...

Eurofins Scientific SE: Weekly report on Share Repurchases on 30th March 2026

LUXEMBOURG--(BUSINESS WIRE)--Regulatory News: Eurofins Scientific SE (Paris:ERF): Name of the Issuer Identify code of the Issuer Transaction day Identify code of the financial instrument Total daily volume (in number of shares) Daily weighted average purchase price of the shares Market (MIC Code) EUROFINS SCIENTIFIC 529900JEHFM47DYY3S57 30/03/2026 FR0014000MR3 4 186 61.7620 XPAR EUROFINS SCIENTIFIC 529900JEHFM47DYY3S57 30/03/2026 FR0014000MR3 1 290 61.7857 CEUX       TOTAL 5 476 61.7676   Trans...
Back to Newsroom